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1. Introduction
Patients with end-stage renal disease (ESRD), especially 
those with acquired cystic disease of the kidney (ACDK) 
secondary to long-term dialysis, are at increased risk 
for renal cell carcinoma (RCC).1 ACDK usually occurs in 
10–20% of patients who have been on dialysis (both peri-
toneal and hemodialysis) for up to 3 years, in 40–60% up 
to 5 years, and more than 90% at more than 10 years.2 
Approximately 3–7% of patients with ACDK develop RCC 
with a risk that is reportedly as high as 100 times compared 
to that in the general population.2 In earlier literature, 
the most common type of RCC arising in the background 
of ACDK was considered to be papillary RCC. However, 
with more extensive analyses, that concept has changed 
dramatically. Although the usual types of RCC as those seen 
in the general population can occur in ESRD patients with 
or without ACDK, the common histologic types of RCC that 
are associated with ESRD and ACDK nowadays are reported 
to be two specific variants. One subtype has only been 
described in patients with ACDK,3,4 and is hence desig-
nated “acquired cystic disease (ACD)-associated RCC” in 
most reports. The other subtype, designated “clear cell 
papillary RCC”, occurs chiefly in patients with ESRD, not 
necessarily in the setting of ACDK.
2. Incidences
Tickoo et al.5 studied 66 ESRD kidneys (52 of which had 
ACDK) and found a total of 261 grossly identifiable tu-
mors and numerous additional microscopic tumors in the 
kidneys. ACD-associated RCC was recognized as the most 
common type, accounting for 36% of dominant masses 
in all ESRD kidneys, as well as 46% in ACDK. Clear cell 
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papillary RCC was identified in 23% of all ESRD kidneys 
regardless of whether or not they showed features of 
ACKD. Other major usual types including papillary RCC, 
clear cell RCC and chromophobe RCC accounted for 18%, 
15% and 8% of dominant masses in ESRD, respectively.
2.1. ACD-associated RCC
ACD-associated RCCs are observed exclusively in the 
background of ACDK. It has not been reported in non-
cystic ESRD and patients without ESRD. It may be de-
tected in patients with clinical renal masses, but more 
often present as an incidental finding in nephrectomies 
performed for other non-tumorous situations. Grossly, 
they are usually small and may be found within cysts. 
Multifocality and bilaterality are not uncommon.
Histologically, ACD-associated RCCs show a spectrum 
of morphologic features, but the presence of eosinophilic 
(oncocytic) cells with at least Furman grade 3 nuclei, and 
cribriform as well as tubulocystic patterns, are consistent 
findings (Figure 1A). Areas with papillary, alveolar, solid 
or diffuse patterns may also be seen, and sometimes 
variable proportions of the tumor may have clear cell cy-
tology. Given the occasional presence of papillary struc-
ture and large eosinophilic cells with prominent nucleoli 
resembling those seen in type 2 papillary RCC, it is plau-
sible that ACD-associated RCC was classified as papillary 
RCC before ACD-associated RCC was recognized as a 
distinct entity. Nevertheless, the distinct cribriform and 
microcystic (sieve-like) growth patterns have never been 
observed in usual papillary RCCs.
One peculiar feature of ACD-associated RCC is the pres-
ence of intratumoral oxalate crystals (CaOx) (Figure 1B).3,4 
Thus, the appellation “oxalate phenotype”4 was created 
for this tumor. CaOx is also observed in renal tubules in 
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non-neoplastic renal parenchyma of ACDK. However, the 
impact of intratumoral CaOx on tumor cells is not clear.6 
CaOx may act as a mitogen at lower concentrations but 
may cause cell necrosis or apoptosis at higher concentra-
tions. In the context of ESRD, CaOx is thought to promote 
cyst and tumor formation through both mechanical ob-
struction of renal tubules and regulation of tubular cell 
cycles. However, the crystals rarely induce foreign body 
reaction and the proliferation activity as measured by 
Ki67 labeling index is not significantly high in ACD-
associated RCC. These features imply that CaOx deposi-
tion may not have a great impact on tumor cell kinetics.
The segment of renal tubule that ACD-associated RCC 
originates from has not been elucidated. ACD-associated 
RCCs are diffusely immunoreactive for alpha-methylacyl-
CoA racemase, CD10, RCC marker, vinculin, glutathione 
S-transferase-alpha, BerEP4 and pan-cytokeratin AE1/3, 
and variably reactive for epithelial membrane antigen, 
vimentin, and low molecular weight cytokeratin. The tu-
mors usually do not express or only focally express CK7, 
high molecular weight cytokeratin, e-cadherin and kidney 
specific cadherin at a low level.4,5,7,8 ACD-associated RCCs 
are labeled by proximal markers at a higher rate than dis-
tal ones, suggesting a probable proximal tubule origin.
The atypical cysts in ACDK are most likely precursors of 
ACD-associated RCC. Histologically, the lining epithelium of 
“atypical cysts” often has eosinophilic cytoplasm and large 
nucleoli similar to that of ACD-associated RCC. Occasion-
ally, there is multilayering of the cystic epithelium with 
formation of papillary tufts or nodular lesions. Keeping 
in line with this speculation, Cheuk et al.9 observed a grad-
ual increase in chromosome gains along with prolifera-
tion of the cystic lining epithelium, leading to multiple 
chromosomal trisomies and polysomies in the carcinoma. 
The accumulative cytogenetic abnormalities lend credence 
to a hypothesis of “adenoma-carcinoma” sequence for 
the emergence of the tumor.
There are only a few published studies to date on 
genetic abnormalities in ACD-associated RCC. Cossu-Rocca 
et al.7 examined three cases using fluorescence in situ 
hybridization with centromeric probes for chromosomes 1, 
2, 6, 10 and 17. They did not find any chromosomal losses 
but they demonstrated multiple chromosomal gains in 
two cases. Our recent study demonstrated non-random 
chromosomal gains clustered on chromosomes 3, 7, 16, Y 
and, less frequently, 17. We also examined the genotypes 
of simultaneously multifocal tumors within the affected 
kidneys. The chromosomal aberrations in all multifocal 
tumors were not identical for the same kidney or for the 
same patient, indicating a “field effect” that induces multi-
focal neoplastic transformation of renal tubular cells.8
2.2. Clear cell papillary RCC
Clear cell papillary RCC was first described by Tickoo et al.5 
in their report of a systematic survey of tumors associ-
ated with ESRD. The tumors were mostly well circum-
scribed and enveloped by a thin capsule. Microscopically, 
the tumors showed a mixed papillary, solid-acinar, tubu-
lar and microcystic pattern. Irrespective of the architec-
ture, the tumors were almost entirely composed of cells 
with clear cytoplasm (Figure 2A). Immunohistochemically, 
the tumor cells were diffusely positive for CK7 (Figure 
2B) but negative for CD10 and alpha-methylacyl-CoA 
racemase.5,10 Since clear cell RCCs do not show papillary 
pattern and they are generally negative for CK7, while 
papillary RCCs are mostly positive for CD10 and alpha-
methylacyl-CoA racemase, the tumor did not belong to 
either category; thus, the hybrid term “clear cell papillary 
RCC” was coined. It should be noted that clear cell papil-
lary RCC is a distinct entity from clear cell RCC and papil-
lary RCC. The tumor is not considered a hybrid or composite 
tumor comprising clear cell RCC and papillary RCC.
Unlike ACD-associated RCC, clear cell papillary RCCs 
also arise in the kidneys of non-cystic ESRD. Recently, 
it was claimed that such tumors are not exclusive to 
ESRD as tumors with similar morphology were reported 
in the normal kidneys of the general population.10 The 
scenario has become more perplexing since a group 
of European pathologists proposed a new entity called 
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Figure 1 (A) Typical microcystic (sieve-like) pattern of acquired cystic disease-associated renal cell carcinoma. (B) Deposition of 
oxalate crystals in the tumor.
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“renal angiomyoadenomous tumor” to describe mor-
phologically overlapping tumors that develop in normal 
kidneys.11 The debate persists as to whether they belong 
to the same category of renal tumors.12
The cytogenetic data about clear cell papillary RCCs 
are limited. Fluorescence in situ hybridization analysis of 
seven clear cell papillary RCCs showed that they all lacked 
the gains of chromosome 7 and losses of chromosome Y 
that are typical of papillary RCC. Only one tumor showed 
a gain of chromosome 17. Deletion of 3p, usually seen in 
clear cell RCC, was not detected.10 However, the seven tu-
mors were all taken from normal kidneys rather than ESRD 
kidneys; therefore, the representativeness of those find-
ings is questioned. Our own experience showed trisomy 
of chromosomes 7 and 17 in one case. Collection of more 
cases is necessary before a conclusion can be drawn.
3. Prognosis
The biologic behavior of RCCs in ESRD is reported to be less 
aggressive than that of RCCs in sporadic or non-ESRD set-
tings. Only rare cases have been reported that show sar-
comatoid changes and metastases.5,13 A possible reason 
for this less aggressive behavior may be that these patients 
are usually under constant medical care, with radiological 
evaluations possibly picking up most tumors quite early.
4. Conclusion
Over the past few years, the field of renal tumor pathology 
has burgeoned with newly defined entities. More and 
more previously “unclassified” RCCs have gained defini-
tive classifications. The recognitions of ACD-associated 
RCC and clear cell papillary RCC are good examples of this 
process. These new entities should not be taken as merely 
an academic exercise that is interesting to pathologists 
alone, but rather seen as progress that may have eventual 
clinical implications. The association of these tumors with 
ESRD also provides clues as to the histogenesis of RCC 
that may shed light on further investigations into RCCs.
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Figure 2 (A) Mixed papillary and acinar pattern in clear cell papillary renal cell carcinoma. (B) The tumor is diffusely immunore-
active for CK7.
